

DAP: TEST  Brands: 

                             n cum_n percent cum_percent
AstraZeneca & AstraZeneca  329   329    4.20        4.20
AstraZeneca & NA           371   700    4.74        8.94
AstraZeneca & Pfizer        13   713    0.17        9.10
J&J & NA                   120   833    1.53       10.63
J&J & Pfizer                 1   834    0.01       10.65
Moderna & Moderna          198  1032    2.53       13.18
Moderna & NA               225  1257    2.87       16.05
NA & NA                   3797  5054   48.47       64.52
Pfizer & AstraZeneca         2  5056    0.03       64.55
Pfizer & NA               1589  6645   20.29       84.83
Pfizer & Pfizer           1188  7833   15.17      100.00


DAP: TEST  Brand: all

                                                                                          label    n  percent
1  total                                                                                        7833 100.0000
2  sex not missing                                                                              4036  51.5256
3  age not missing                                                                              4036  51.5256
4  received at least one vaccine dose of any brand                                              4036  51.5256
5  vaccine brand not missing                                                                    4036  51.5256
6  at least one myopericarditis diagnosis ever                                                     6   0.0766
7  at least one myopericarditis diagnosis in time period of interest (starts 1sep2020)             2   0.0255
8  at least one myopericarditis diagnosis within study period (starts at control window)           2   0.0255
9  at least one myopericarditis diagnosis between start control and end last 28-day risk window    2   0.0255
10 excluding myopericarditis diagnoses occuring between 28-day risk window 1 and 2                 2   0.0255
11 excluding myopericarditis diagnoses occuring during the buffer period (28 day risk windows)     1   0.0128
12 at least one myopericarditis diagnosis between start control and end last 60-day risk window    2   0.0255
13 excluding myopericarditis diagnoses occuring between 60-day risk window 1 and 2                 2   0.0255
14 excluding myopericarditis diagnoses occuring during the buffer period (60 day risk windows)     1   0.0128


DAP: TEST  Brands for included persons: 

                     n cum_n percent cum_percent
Pfizer & AstraZeneca 1     1      50          50
Pfizer & NA          1     2      50         100


DAP: TEST  Brand: all   "Interaction"-Table:

                                                                                                                                                                     n cum_n percent cum_percent
   sex    age    vax1    vax1_type    myoperi   from_sep2020   from_vax1-90  till_last_rw28d not_betw_rw1_rw2_28d  till_last_rw60d not_betw_rw1_rw2_60d    buffer    1     1    0.01        0.01
   sex    age    vax1    vax1_type    myoperi   from_sep2020   from_vax1-90  till_last_rw28d not_betw_rw1_rw2_28d  till_last_rw60d not_betw_rw1_rw2_60d no_buffer    1     2    0.01        0.03
   sex    age    vax1    vax1_type    myoperi before_sep2020 before_vax1-90  till_last_rw28d not_betw_rw1_rw2_28d  till_last_rw60d not_betw_rw1_rw2_60d no_buffer    4     6    0.05        0.08
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d     betw_rw1_rw2_28d after_last_rw60d     betw_rw1_rw2_60d    buffer 1729  1735   22.07       22.15
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d not_betw_rw1_rw2_28d after_last_rw60d not_betw_rw1_rw2_60d    buffer 2301  4036   29.38       51.53
no_sex no_age no_vax1 no_vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d not_betw_rw1_rw2_28d after_last_rw60d not_betw_rw1_rw2_60d    buffer 3797  7833   48.47      100.00


DAP: TEST  Brand: all   "Interaction"-Table for riks windows of 28 days:

                                                                                                                               n cum_n percent cum_percent
   sex    age    vax1    vax1_type    myoperi   from_sep2020   from_vax1-90  till_last_rw28d not_betw_rw1_rw2_28d    buffer    1     1    0.01        0.01
   sex    age    vax1    vax1_type    myoperi   from_sep2020   from_vax1-90  till_last_rw28d not_betw_rw1_rw2_28d no_buffer    1     2    0.01        0.03
   sex    age    vax1    vax1_type    myoperi before_sep2020 before_vax1-90  till_last_rw28d not_betw_rw1_rw2_28d no_buffer    4     6    0.05        0.08
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d     betw_rw1_rw2_28d    buffer 1729  1735   22.07       22.15
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d not_betw_rw1_rw2_28d    buffer 2301  4036   29.38       51.53
no_sex no_age no_vax1 no_vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d not_betw_rw1_rw2_28d    buffer 3797  7833   48.47      100.00


DAP: TEST  Brand: all   "Interaction"-Table for riks windows of 60 days:

                                                                                                                               n cum_n percent cum_percent
   sex    age    vax1    vax1_type    myoperi   from_sep2020   from_vax1-90  till_last_rw60d not_betw_rw1_rw2_60d    buffer    1     1    0.01        0.01
   sex    age    vax1    vax1_type    myoperi   from_sep2020   from_vax1-90  till_last_rw60d not_betw_rw1_rw2_60d no_buffer    1     2    0.01        0.03
   sex    age    vax1    vax1_type    myoperi before_sep2020 before_vax1-90  till_last_rw60d not_betw_rw1_rw2_60d no_buffer    4     6    0.05        0.08
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw60d     betw_rw1_rw2_60d    buffer 1729  1735   22.07       22.15
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw60d not_betw_rw1_rw2_60d    buffer 2301  4036   29.38       51.53
no_sex no_age no_vax1 no_vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw60d not_betw_rw1_rw2_60d    buffer 3797  7833   48.47      100.00


DAP: TEST  Brand: AstraZeneca

                                                                                          label   n percent
1  total                                                                                        713     100
2  sex not missing                                                                              713     100
3  age not missing                                                                              713     100
4  received at least one vaccine dose of any brand                                              713     100
5  vaccine brand not missing                                                                    713     100
6  at least one myopericarditis diagnosis ever                                                    0       0
7  at least one myopericarditis diagnosis in time period of interest (starts 1sep2020)            0       0
8  at least one myopericarditis diagnosis within study period (starts at control window)          0       0
9  at least one myopericarditis diagnosis between start control and end last 28-day risk window   0       0
10 excluding myopericarditis diagnoses occuring between 28-day risk window 1 and 2                0       0
11 excluding myopericarditis diagnoses occuring during the buffer period (28 day risk windows)    0       0
12 at least one myopericarditis diagnosis between start control and end last 60-day risk window   0       0
13 excluding myopericarditis diagnoses occuring between 60-day risk window 1 and 2                0       0
14 excluding myopericarditis diagnoses occuring during the buffer period (60 day risk windows)    0       0


DAP: TEST  Brand: AstraZeneca   "Interaction"-Table:

                                                                                                                                                                    n cum_n percent cum_percent
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d     betw_rw1_rw2_28d after_last_rw60d     betw_rw1_rw2_60d    buffer 342   342   47.97       47.97
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d not_betw_rw1_rw2_28d after_last_rw60d not_betw_rw1_rw2_60d    buffer 371   713   52.03      100.00


DAP: TEST  Brand: AstraZeneca   "Interaction"-Table for riks windows of 28 days:

                                                                                                                              n cum_n percent cum_percent
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d     betw_rw1_rw2_28d    buffer 342   342   47.97       47.97
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d not_betw_rw1_rw2_28d    buffer 371   713   52.03      100.00


DAP: TEST  Brand: AstraZeneca   "Interaction"-Table for riks windows of 60 days:

                                                                                                                              n cum_n percent cum_percent
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw60d     betw_rw1_rw2_60d    buffer 342   342   47.97       47.97
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw60d not_betw_rw1_rw2_60d    buffer 371   713   52.03      100.00


DAP: TEST  Brand: J&J

                                                                                          label   n percent
1  total                                                                                        121     100
2  sex not missing                                                                              121     100
3  age not missing                                                                              121     100
4  received at least one vaccine dose of any brand                                              121     100
5  vaccine brand not missing                                                                    121     100
6  at least one myopericarditis diagnosis ever                                                    0       0
7  at least one myopericarditis diagnosis in time period of interest (starts 1sep2020)            0       0
8  at least one myopericarditis diagnosis within study period (starts at control window)          0       0
9  at least one myopericarditis diagnosis between start control and end last 28-day risk window   0       0
10 excluding myopericarditis diagnoses occuring between 28-day risk window 1 and 2                0       0
11 excluding myopericarditis diagnoses occuring during the buffer period (28 day risk windows)    0       0
12 at least one myopericarditis diagnosis between start control and end last 60-day risk window   0       0
13 excluding myopericarditis diagnoses occuring between 60-day risk window 1 and 2                0       0
14 excluding myopericarditis diagnoses occuring during the buffer period (60 day risk windows)    0       0


DAP: TEST  Brand: J&J   "Interaction"-Table:

                                                                                                                                                                    n cum_n percent cum_percent
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d     betw_rw1_rw2_28d after_last_rw60d     betw_rw1_rw2_60d    buffer   1     1    0.83        0.83
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d not_betw_rw1_rw2_28d after_last_rw60d not_betw_rw1_rw2_60d    buffer 120   121   99.17      100.00


DAP: TEST  Brand: J&J   "Interaction"-Table for riks windows of 28 days:

                                                                                                                              n cum_n percent cum_percent
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d     betw_rw1_rw2_28d    buffer   1     1    0.83        0.83
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d not_betw_rw1_rw2_28d    buffer 120   121   99.17      100.00


DAP: TEST  Brand: J&J   "Interaction"-Table for riks windows of 60 days:

                                                                                                                              n cum_n percent cum_percent
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw60d     betw_rw1_rw2_60d    buffer   1     1    0.83        0.83
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw60d not_betw_rw1_rw2_60d    buffer 120   121   99.17      100.00


DAP: TEST  Brand: Moderna

                                                                                          label   n percent
1  total                                                                                        423 100.000
2  sex not missing                                                                              423 100.000
3  age not missing                                                                              423 100.000
4  received at least one vaccine dose of any brand                                              423 100.000
5  vaccine brand not missing                                                                    423 100.000
6  at least one myopericarditis diagnosis ever                                                    2   0.473
7  at least one myopericarditis diagnosis in time period of interest (starts 1sep2020)            0   0.000
8  at least one myopericarditis diagnosis within study period (starts at control window)          0   0.000
9  at least one myopericarditis diagnosis between start control and end last 28-day risk window   0   0.000
10 excluding myopericarditis diagnoses occuring between 28-day risk window 1 and 2                0   0.000
11 excluding myopericarditis diagnoses occuring during the buffer period (28 day risk windows)    0   0.000
12 at least one myopericarditis diagnosis between start control and end last 60-day risk window   0   0.000
13 excluding myopericarditis diagnoses occuring between 60-day risk window 1 and 2                0   0.000
14 excluding myopericarditis diagnoses occuring during the buffer period (60 day risk windows)    0   0.000


DAP: TEST  Brand: Moderna   "Interaction"-Table:

                                                                                                                                                                    n cum_n percent cum_percent
   sex    age    vax1    vax1_type    myoperi before_sep2020 before_vax1-90  till_last_rw28d not_betw_rw1_rw2_28d  till_last_rw60d not_betw_rw1_rw2_60d no_buffer   2     2    0.47        0.47
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d     betw_rw1_rw2_28d after_last_rw60d     betw_rw1_rw2_60d    buffer 198   200   46.81       47.28
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d not_betw_rw1_rw2_28d after_last_rw60d not_betw_rw1_rw2_60d    buffer 223   423   52.72      100.00


DAP: TEST  Brand: Moderna   "Interaction"-Table for riks windows of 28 days:

                                                                                                                              n cum_n percent cum_percent
   sex    age    vax1    vax1_type    myoperi before_sep2020 before_vax1-90  till_last_rw28d not_betw_rw1_rw2_28d no_buffer   2     2    0.47        0.47
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d     betw_rw1_rw2_28d    buffer 198   200   46.81       47.28
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d not_betw_rw1_rw2_28d    buffer 223   423   52.72      100.00


DAP: TEST  Brand: Moderna   "Interaction"-Table for riks windows of 60 days:

                                                                                                                              n cum_n percent cum_percent
   sex    age    vax1    vax1_type    myoperi before_sep2020 before_vax1-90  till_last_rw60d not_betw_rw1_rw2_60d no_buffer   2     2    0.47        0.47
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw60d     betw_rw1_rw2_60d    buffer 198   200   46.81       47.28
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw60d not_betw_rw1_rw2_60d    buffer 223   423   52.72      100.00


DAP: TEST  Brand: Pfizer

                                                                                          label    n percent
1  total                                                                                        2779 100.000
2  sex not missing                                                                              2779 100.000
3  age not missing                                                                              2779 100.000
4  received at least one vaccine dose of any brand                                              2779 100.000
5  vaccine brand not missing                                                                    2779 100.000
6  at least one myopericarditis diagnosis ever                                                     4   0.144
7  at least one myopericarditis diagnosis in time period of interest (starts 1sep2020)             2   0.072
8  at least one myopericarditis diagnosis within study period (starts at control window)           2   0.072
9  at least one myopericarditis diagnosis between start control and end last 28-day risk window    2   0.072
10 excluding myopericarditis diagnoses occuring between 28-day risk window 1 and 2                 2   0.072
11 excluding myopericarditis diagnoses occuring during the buffer period (28 day risk windows)     1   0.036
12 at least one myopericarditis diagnosis between start control and end last 60-day risk window    2   0.072
13 excluding myopericarditis diagnoses occuring between 60-day risk window 1 and 2                 2   0.072
14 excluding myopericarditis diagnoses occuring during the buffer period (60 day risk windows)     1   0.036


DAP: TEST  Brand: Pfizer   "Interaction"-Table:

                                                                                                                                                                     n cum_n percent cum_percent
   sex    age    vax1    vax1_type    myoperi   from_sep2020   from_vax1-90  till_last_rw28d not_betw_rw1_rw2_28d  till_last_rw60d not_betw_rw1_rw2_60d    buffer    1     1    0.04        0.04
   sex    age    vax1    vax1_type    myoperi   from_sep2020   from_vax1-90  till_last_rw28d not_betw_rw1_rw2_28d  till_last_rw60d not_betw_rw1_rw2_60d no_buffer    1     2    0.04        0.07
   sex    age    vax1    vax1_type    myoperi before_sep2020 before_vax1-90  till_last_rw28d not_betw_rw1_rw2_28d  till_last_rw60d not_betw_rw1_rw2_60d no_buffer    2     4    0.07        0.14
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d     betw_rw1_rw2_28d after_last_rw60d     betw_rw1_rw2_60d    buffer 1188  1192   42.75       42.89
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d not_betw_rw1_rw2_28d after_last_rw60d not_betw_rw1_rw2_60d    buffer 1587  2779   57.11      100.00


DAP: TEST  Brand: Pfizer   "Interaction"-Table for riks windows of 28 days:

                                                                                                                               n cum_n percent cum_percent
   sex    age    vax1    vax1_type    myoperi   from_sep2020   from_vax1-90  till_last_rw28d not_betw_rw1_rw2_28d    buffer    1     1    0.04        0.04
   sex    age    vax1    vax1_type    myoperi   from_sep2020   from_vax1-90  till_last_rw28d not_betw_rw1_rw2_28d no_buffer    1     2    0.04        0.07
   sex    age    vax1    vax1_type    myoperi before_sep2020 before_vax1-90  till_last_rw28d not_betw_rw1_rw2_28d no_buffer    2     4    0.07        0.14
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d     betw_rw1_rw2_28d    buffer 1188  1192   42.75       42.89
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw28d not_betw_rw1_rw2_28d    buffer 1587  2779   57.11      100.00


DAP: TEST  Brand: Pfizer   "Interaction"-Table for riks windows of 60 days:

                                                                                                                               n cum_n percent cum_percent
   sex    age    vax1    vax1_type    myoperi   from_sep2020   from_vax1-90  till_last_rw60d not_betw_rw1_rw2_60d    buffer    1     1    0.04        0.04
   sex    age    vax1    vax1_type    myoperi   from_sep2020   from_vax1-90  till_last_rw60d not_betw_rw1_rw2_60d no_buffer    1     2    0.04        0.07
   sex    age    vax1    vax1_type    myoperi before_sep2020 before_vax1-90  till_last_rw60d not_betw_rw1_rw2_60d no_buffer    2     4    0.07        0.14
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw60d     betw_rw1_rw2_60d    buffer 1188  1192   42.75       42.89
   sex    age    vax1    vax1_type no_myoperi before_sep2020 before_vax1-90 after_last_rw60d not_betw_rw1_rw2_60d    buffer 1587  2779   57.11      100.00
